Clinical Trial

Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

Name: Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC — clinical trial record (NCT07663747)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FIDELIO

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase 2 clinical intervention trial to assess efficacy of induction EVP to spare the bladder in stage T2-4aN0-1 urothelial bladder cancer (UBC), using a response-adapted approach

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-06-18.

Trial Details

NCT Number	NCT07663747
Lead Sponsor	The Netherlands Cancer Institute Collaborators: Merck Sharp & Dohme LLC, Astellas Pharma Inc
Conditions	Urothelial Bladder Cancer
Enrollment	56 participants
Start Date	2026-09-01
Primary Completion	2031-04-01 (estimated)
Study Completion	2032-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-25